Compounds for use in treating neurological disorders
WO2021016409A1
Ezh2 inhibition in combination therapies for the treatment of cancers
WO2021016414A1
Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
WO2021016317A1
Modulators of trex1
WO2020257644A1
Methods of treating myeloproliferative disorders
WO2020223590A1
Modulators of trex1
WO2020176558A1
P300/cbp hat inhibitors and methods for their use
WO2020118133A1
Modulators of trex1
WO2020112939A1
Methods of treating myeloproliferative disorders
WO2020256739A1
Methods of treating myeloproliferative disorders
WO2019226491A1
Modulators of methyl modifying enzymes, compositions and uses thereof
KR20210003160A
Methyl modifying enzyme modulators, compositions and uses thereof
EP3752250A1
P300/cbp hat inhibitors
US2021115008A1
P300/cbp hat inhibitors
CN111757734A
Pharmacokinetic enhancement of EZH2 inhibitors by combination therapy
WO2020139339A1
Ezh2 and androgen receptor signaling inhibitors as tools for targeting prostate cancer
WO2020112086A1
Methods of treating myeloproliferative disorders
EP3707136A1
Modulators of methyl modifying enzymes, compositions and uses thereof
WO2019014191A1
Ezh2 inhibitor-induced gene expression
AU2018210141A1
Solid dispersions of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
